Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-α therapy: Phenotypic and functional characterization up to 20 months after initial tumor inoculation

International Journal of Cancer

Volumn 76, Issue 4, 1998, Pages 579-586

  Ehrke, M Jane ^a   Verstovsek, Srdan ^a   Pocchiari, Susan K ^a   Krawczyk, Christian M ^a   Ujhaźy, Peter ^a   Zaleskis, Gintaras ^a   Maccubbin, Darbie L ^a   Meer, Jane M ^a   Mihich, Enrico ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; HERMES ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; THYMOCYTE; TUMOR REJECTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; LEUKEMIA, MYELOID; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PHENOTYPE; THYMUS GLAND; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031960216     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980518)76:4<579::AID-IJC22>3.0.CO;2-1     Document Type: Article

References (29)

1. AGUS, D.B., SURH, C.D. and SPRENT, J., Reentry of T cells to the adult thymus is restricted to activated T cells. J. Exp. Med., 173, 1039-1046, (1991).
2. AHMED, R. and GRAY, D., Immunological memory and protective immunity: understanding their relation. Science, 272, 54-60, (1996).
3. ALLISON, J. and KRUMMEL, M., The yin and yang of T cell costimulation. Science, 270, 932-933, (1995).
4. CHOYKE, P.L., ZEMAN, R.K., GOOTENBERG, J.E., GREENBERG, J.N., HOFFER, F. and FRANK, J.A., Thymic atrophy and regrowth in response to chemotherapy : CT evaluation. Amer. J. Roentgenol., 149, 269-272, (1987).
5. COLVIN, O.M., Alkylating agents and platinum antitumor compounds, In: J.F. Holland, E. Frei III, R.C. Bast Jr., D.W. Kufe, D.L. Morton and R.R. Weichselbaum (eds.), Cancer medicine, pp. 949-976. Williams & Wilkins, Baltimore (1997).
6. EGGERMONT, A.M.M., SCHRAFFORDT KOOPS, H., LIÉNARD, D., KROON, B.B., VAN GEEL, A.N., HOEKSTRA, H.J. and LEJEUNE, F.J., Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol., 14, 2653-2665, (1996).
7. EHRKE, M.J., Effect of cancer therapy on host response and immunobiology. Curr. Opin. Oncol., 3, 1070-1077 (1991).
8. EHRKE, M.J., Ho, R.L. and HORI, K., Species-specific TNF induction of thymocyte proliferation. Cancer Immunol. Immunother., 27, 103-108, (1988).
9. EHRKE, M.J., MIHICH, E., BERD, D. and MASTRANGELO, M.J., Effects of anticancer drugs on the immune system in humans. Semin. Oncol., 16, 230-253, (1989).
10. EHRKE, M.J., VERSTOVSEK, S., KRAWCZYK, C.M., UJHÁZY, P., ZALESKIS, G., MACCUBBIN, D.L., and MIHICH, E., CYCLOPHOSPHAMIDE plus tumor necrosis factor-α chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int. J. Cancer. 63, 463-471, (1995).
11. FRAKER, D.L., and ALEXANDER, H.R., Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. Import. Adv. Oncol., 1, 179-192, (1994).
12. HO, R.L.X., MACCUBBIN, D., UJHÁZY, P., ZALESKIS, G., EPPOLITO,C., MIHICH, E. and EHRKE, M.J. Immunological responses critical to the therapeutic effects of Adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol. Res., 5, 363-372, (1993a).
13. HO, R.L.X., MACCUBBIN, D., ZALESKIS, G., KRAWCZYK, C., WING, K., MIHICH, E. and EHRKE, M.J., Development of a safe and effective Adriamycin plus interleukin 2 therapy against both Adriamycin-sensitive and -resistant lymphomas. Oncol. Res., 5, 373-381, (1993b).
14. KELLY, K.A., BUCY, R.P. and NAHM, M.H., Germinal center T cells exhibit properties of memory helper T cells. Cell. Immunol., 163, 206-214, (1995).
15. KRAWCZYK, C.M., VERSTOVSEK, S., UJHÁZY, P., MACCUBIN, D. and EHRKE, M.J., Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor α combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol. Immunother., 40, 347-357, (1995).
16. KÜNDIG, T.M., BACHMANN, M., OHASHI, P., PIRCHER, H., HENGARTNER, H. and ZINKERNAGEL, R., On T cell memory: arguments for antigen dependence. Immunol. Rev., 150, 63-90. (1996).
17. LEDERER, J.A., LIOU, J.S., KIM, S., RICE, N. and LICHTMAN, A.H., Regulation of NF-κB activation in T helper 1 and T helper 2 cells. J. Immunol., 156, 56-63, (1996).
18. MACCUBBIN, D., MACE, K., EHRKE, M.J. and MIHICH, E., Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res., 49, 4216-4224. (1989).
19. MASTRANGELO, M.J., MAGUIRE, H.C., Jr., SATO, B., NATHAN, F.E. and BERD, D., Active specific immunization in the treatment of patients with melanoma. Semin. Oncol., 23, 773-781, (1996).
20. MATZINGER, P., Tolerance, danger, and the extended family. Ann. Rev. Immunol., 12, 991-1045, (1994).
21. MIHICH, E. and EHRKE, M.J., Immunomodulation by anticancer drugs. In: V.T.J. DeVita, S. Hellnam and S.A. Rosenberg, (eds.). Biologic therapy of cancer: principles and practice, pp. 776-786. J.B. Lippincott Philadelphia. (1991).
22. NAHM, M.H., KROESE, F.G. and HOFFMANN, J.W., The evolution of immune memory and germinal centers. Immunol. Today. 13, 438-441, (1992).
23. PARDOLL, D., Releasing the brakes on antitumor immune response. Science, 271, 1691, (1996).
24. SIDHU, R.S. and BOLLON, A.P., Tumor necrosis factor activities and cancer therapy - a perspective. Pharmacol. Therap., 57:79-128, (1993).
25. SPRENT, J., T and B memory cells. Cell. 76, 315-322, (1994).
26. UJHÁZY, P., CHEN, Y., FRKDERICKS, W., HO, R., BAKER, R., MIHICH, E. and EHRKE, M.J., The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model. Cancer Comm., 2, 181-188, (1990).
27. YOSHIDA, J., WAKABAYASHI, T., MIZUNO, M., SUGITA, K., YOSHIDA, T., HORI, S., MORI, T., SATO, T., KARASHIMA, A. and KURISU, K., Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J. Neurosurg., 77, 78-83, (1992).
28. ZALESKIS, G., BERLETH, E., EHRKE, M.J. and MIHICH, E., Doxorubicin-induced DNA degradation in murine thymocytes. Mol. Pharmacol., 46, 901-908, (1994).
29. ZHENG, L., FISHER, G., MILLER, R.E., PESCHON, J., LYNCH, D.H. and LENARDO, M.J., Induction of apoptosis in mature T cells by tumor necrosis factor. Nature (Lond.) 377, 384-391, (1995).